Cargando…

Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC

The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in patient prognosis. Disappointingly, the success of ICI therapy in NSCLC has not been fully replicated i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cantini, Luca, Pecci, Federica, Merloni, Filippo, Lanese, Andrea, Lenci, Edoardo, Paoloni, Francesco, Aerts, Joachim G.J.V., Berardi, Rossana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400728/ https://www.ncbi.nlm.nih.gov/pubmed/36046087 http://dx.doi.org/10.37349/etat.2021.00030

Ejemplares similares

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
por: Lenci, Edoardo, et al.
Publicado: (2021)

Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing
por: Giampieri, Riccardo, et al.
Publicado: (2020)

Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic
por: Ballatore, Zelmira, et al.
Publicado: (2020)

Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer
por: Bittoni, Alessandro, et al.
Publicado: (2021)

Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis
por: Lenci, Edoardo, et al.
Publicado: (2021)

Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers
por: Parisi, Alessandro, et al.
Publicado: (2023)

Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
por: Pistelli, Mirco, et al.
Publicado: (2021)

Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia
por: Giampieri, Riccardo, et al.
Publicado: (2019)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma
por: Cornelissen, Robin, et al.
Publicado: (2007)

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives
por: Cognigni, Valeria, et al.
Publicado: (2022)

1757P Training and information during COVID-19 pandemic: The masterpiece in young oncologists
por: Ranallo, N., et al.
Publicado: (2020)

Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours
por: Dumoulin, Daphne W., et al.
Publicado: (2023)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

1684P Scientia Potentia Est: How the Italian world of oncology changes in the COVID-19 pandemic
por: Ballatore, Z., et al.
Publicado: (2020)

An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2021)

The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience
por: Pistelli, Mirco, et al.
Publicado: (2021)

Tracking Actomyosin at Fluorescence Check Points
por: Lard, Mercy, et al.
Publicado: (2013)

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
por: Belderbos, Robert A., et al.
Publicado: (2019)

Cancer patient perspective in the arena of COVID‐19 pandemic
por: Ballatore, Zelmira, et al.
Publicado: (2021)

Are liver nested stromal epithelial tumors always low aggressive?
por: Meletani, Tania, et al.
Publicado: (2017)

Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018)

Immune Check Point Inhibitor–Associated Endothelialitis
por: Bobart, Shane A., et al.
Publicado: (2020)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
por: Maccaroni, Elena, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy
por: Cantini, Luca, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Check Point NG : next generation security administration
por: Simonis, Drew
Publicado: (2002)

Check Point NGX R65 Security Administration
por: Bonnell, Ralph
Publicado: (2008)

Novel Immune Check-Point Regulators in Tolerance Maintenance
por: Guo, Yanxia, et al.
Publicado: (2015)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

The distress thermometer as a predictor for survival in stage III lung cancer patients treated with chemotherapy
por: de Mol, Mark, et al.
Publicado: (2016)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
por: Bittoni, Alessandro, et al.
Publicado: (2021)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Erratum: Novel Immune Check-Point Regulators in Tolerance Maintenance
Publicado: (2016)

Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy
por: Vergne-Santiago, Norma, et al.
Publicado: (2021)

FRI332 Check Point Inhibitor Induced Hypophysitis/Hypopituitarism
por: Chandpuri, Ranjit Singh
Publicado: (2023)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oavqgjdkgmp2f0sl24pm5k8bap